In catheterization laboratories and interventional suites, treating acute peripheral arterial occlusions and extensive deep vein thrombosis has historically required a frustrating physical compromise. Continuous vacuum aspiration catheters exert high static negative pressure (up to 29 inHg) to ingest organized, fibrin-rich clot. However, continuous suction frequently causes the catheter tip to adhere to the vascular endothelial wall, collapsing small vessels and aspirating substantial volumes of healthy blood before the thrombus is fully extracted.

The FDA 510(k) clearance granted on September 28, 2026, to Insera Therapeutics for the CLEAR Aspiration System introduces a mechanical evolution designed to break this tradeoff. By modulating vacuum pressure through proprietary cyclical oscillations, the system disrupts the static friction of stubborn clots while minimizing procedural blood loss, establishing a new technological paradigm in peripheral revascularization.

In this deep dive

  • Why this matters now: the clinical tradeoff in peripheral mechanical thrombectomy
  • What actually happened: inside Insera's FDA 510(k) clearance (K253404)
  • The obvious read versus the deeper signal
  • Endovascular thrombectomy taxonomy: comparing leading device architectures
  • Cath lab economics: blood transfusion avoidance and procedure time compression
  • The counter-thesis and four clinical milestones to track

Why this matters now: the clinical tradeoff in peripheral mechanical thrombectomy

Peripheral artery disease (PAD) and deep vein thrombosis (DVT) affect more than 20 million Americans, resulting in hundreds of thousands of revascularization procedures annually. While surgical embolectomy and catheter-directed thrombolysis carried high hemorrhage risks, first-generation mechanical aspiration devices introduced their own operational challenges: excessive blood loss often requiring intraoperative autotransfusion or blood bank products, and incomplete clot extraction leading to secondary passes and distal embolization.

What actually happened: inside Insera's FDA 510(k) clearance (K253404)

Insera Therapeutics (led by CEO Vikram Janardhan and Medical Director Dr. Vallabh Janardhan) secured FDA 510(k) clearance under 21 CFR 870.5150 (Embolectomy catheter, Class II, Product Code QEZ). Supported by key clinical leaders including Dr. Italo Linfante of the Miami Cardiac and Vascular Institute, the CLEAR system incorporates:

  • CLEAR Digital Aspiration Pump: Sits outside the sterile field, driving vacuum pressures from 0 to 29 inHg.
  • Selectable Operating Modes: Offers Cyclical mode (rapid pressure modulation to dislodge thrombus), Uniform mode (continuous standard suction), and Blood Saver mode (intermittent pulsed aspiration to curb blood loss).
  • Single-Use Delivery Disposables: Includes custom INSERA catheters, aspiration tubing, and pre-assembled non-sterile collection canisters, supplementing existing European CE Mark commercialization.